Market revenue in 2023 | USD 502.0 million |
Market revenue in 2030 | USD 1,545.3 million |
Growth rate | 17.4% (CAGR from 2023 to 2030) |
Largest segment | Antisense rna |
Fastest growing segment | RNA Interference |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | RNA Interference, Antisense RNA |
Key market players worldwide | GSK PLC, Sanofi SA, Alnylam Pharmaceuticals Inc, Arbutus Biopharma Corp, Benitec Biopharma Inc, Silence Therapeutics PLC, Ionis Pharmaceuticals Inc, Sarepta Therapeutics Inc, Percheron Therapeutics Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antisense and rnai therapeutics market will help companies and investors design strategic landscapes.
Antisense rna was the largest segment with a revenue share of 72.73% in 2024. Horizon Databook has segmented the Asia Pacific antisense and rnai therapeutics market based on rna interference, antisense rna covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific antisense and rnai therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific antisense and rnai therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account